Page last updated: 2024-08-05 10:55:01
pyrazines
null
ChEBI ID: 38314
Members (47)
| Member | Definition | Role |
|---|---|---|
| 2-aminopyrazine | Aminopyrazine | |
| 2-chloropyrazine | 2-chloropyrazine | |
| 2-ethyl-3,5-dimethylpyrazine | 2-Ethyl-3,5-dimethylpyrazine | |
| 2-methoxy-N-methyl-N-[5-(5-methyl-2-pyrazinyl)-1,3,4-thiadiazol-2-yl]acetamide | 2-methoxy-N-methyl-N-[5-(5-methyl-2-pyrazinyl)-1,3,4-thiadiazol-2-yl]acetamide | |
| 2,3-Diethyl-5-methylpyrazine | 2,3-Diethyl-5-methylpyrazine | |
| 2,3-Dimethylpyrazine | 2,3-Dimethylpyrazine | |
| 2,3-diphenylpyrazine | 2,3-diphenylpyrazine | |
| 2,3,5-trimethylpyrazine | A member of the class of pyrazines that is pyrazine in which three hydrogens at positions 2, 3 and 5 have been replaced by methyl groups. | trimethylpyrazine |
| 2,5-dimethylpyrazine | 2,5-Dimethylpyrazine | |
| 2,6-bis(1-pyrazolyl)pyrazine | 2,6-bis(1-pyrazolyl)pyrazine | |
| 3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylene)piperazine-2,5-dione | 3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylene)piperazine-2,5-dione | |
| 3,5-Dimethylpyrazin-2-amine | 3,5-Dimethylpyrazin-2-amine | |
| 3',4'-dichlorobenzamil | 3,5-diamino-N-[amino-[(3,4-dichlorophenyl)methylimino]methyl]-6-chloro-2-pyrazinecarboxamide | |
| 5-(n,n-hexamethylene)amiloride | A member of the class of pyrazines that is amiloride in which the two amino hydrogens at position N-5 are replaced by a hexamethylene moiety, resulting in the formation of an azepane ring. | 5-(N,N-hexamethylene)amiloride |
| 5-hydroxypyrazinamide | 5-Hydroxypyrazinamide | |
| 6-chloro-3,5-diaminopyrazine-3-carboxamide | 6-chloro-3,5-diaminopyrazine-3-carboxamide | |
| amiloride | A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid. | amiloride |
| aspergillic acid | Aspergillic acid | |
| azd2858 | A member of the class of pyrazines that is pyrazine substituted by (pyridin-3-yl)aminocarbonyl, amino, and 4-(4-methylpiperazine-1-sulfonyl)phenyl groups at positions 2, 3 and 6, respectively. It is a potent inhibitor of GSK3alpha and GSK3beta (IC50 values of 0.9 and 4.9 nM, respectively) and increases bone mass (via Wnt activation) in rats. | AZD2858 |
| benzamil | Benzamil | |
| bortezomib | L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at N(alpha) by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome. | bortezomib |
| cx 5461 | An organic heterotetracyclic compound that is 5-oxo-5H-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxylic acid substituted by a 4-methyl-1,4-diazepan-1-yl group at position 2 and in which the carboxy group at position 6 is substituted by a [(5-methylpyrazin-2-yl)methyl]nitrilo group. An inhibitor of ribosomal RNA (rRNA) synthesis which specifically inhibits RNA polymerase I-driven transcription of rRNA in several cancer cell lines. It is currently in phase I/II clinical trials for advanced hematologic malignancies and triple-negative breast cancer with BRCA1/2 mutation. | CX-5461 |
| cyanopyrazine | cyanopyrazine | |
| ethylisopropylamiloride | A member of the class of pyrazines that is amiloride in which the amino substitutent of the pyrazine ring that is adjacent to the chloro substituent has been substituted by an ethyl group and by an isopropyl group. | ethylisopropylamiloride |
| gilteritinib | A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation. | gilteritinib |
| glipizide | An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus. | glipizide |
| isradipine | oxidized Oplophorus luciferin | |
| lgk974 | A carboxamide, the structure of which is that of acetamide substituted on carbon by a 2',3-dimethyl-2,4'-bipyridin-5-yl group and on nitrogen by a 5-(pyrazin-2-yl)pyridin-2-yl group. It is a highly potent, selective and orally bioavailable Porcupine inhibitor (a Wnt signalling inhibitor). | LGK974 |
| methyl 3-aminopyrazine-2-carboxylate | A pyrazine that is substituted by a methoxycarbonyl group at position 2 and an amino group at position 3. | methyl 3-aminopyrazine-2-carboxylate |
| morphazinamide | morinamide | |
| mre 269 | A member of the class of pyrazines that is {4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetic acid carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. The active metabolite of selexipag, an orphan drug used for the treatment of pulmonary arterial hypertension. | ACT-333679 |
| N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-pyrazinecarboxamide | N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-pyrazinecarboxamide | |
| n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide | A sulfonamide that is a 3-methoxypyrazin-2-yl derivative of (E)-N-(4-(N-(4,6-dimethylpyrimidin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide. Necrosulfonamide specifically blocks necrosis downstream of the activation of RIP3 (the receptor-interacting serine-threonine kinase 3), a key signalling molecule in the programmed necrosis (necroptosis) pathway. | necrosulfonamide |
| N-[1-[(4-chlorophenyl)methyl]-4-pyrazolyl]-2-pyrazinecarboxamide | N-[1-[(4-chlorophenyl)methyl]-4-pyrazolyl]-2-pyrazinecarboxamide | |
| N-[5-[(2,6-dichlorophenyl)methylthio]-1,3,4-thiadiazol-2-yl]-5-methyl-2-pyrazinecarboxamide | N-[5-[(2,6-dichlorophenyl)methylthio]-1,3,4-thiadiazol-2-yl]-5-methyl-2-pyrazinecarboxamide | |
| N-methyl-N-[5-(5-methyl-2-pyrazinyl)-1,3,4-thiadiazol-2-yl]-2-oxolanecarboxamide | N-methyl-N-[5-(5-methyl-2-pyrazinyl)-1,3,4-thiadiazol-2-yl]-2-oxolanecarboxamide | |
| N'-[1-oxo-2-(4-propan-2-ylphenoxy)ethyl]-2-pyrazinecarbohydrazide | N'-[1-oxo-2-(4-propan-2-ylphenoxy)ethyl]-2-pyrazinecarbohydrazide | |
| N'-[2-(4-bromo-2-methylphenoxy)-1-oxoethyl]-2-pyrazinecarbohydrazide | N'-[2-(4-bromo-2-methylphenoxy)-1-oxoethyl]-2-pyrazinecarbohydrazide | |
| oltipraz | A 1,2-dithiole that is 3H-1,2-dithiole-3-thione substituted at positions 4 and 5 by methyl and pyrazin-2-yl groups respectively. | oltipraz |
| phenylamil | Phenylamil | |
| pyrazinamide | A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis. | pyrazinecarboxamide |
| pyrazines | A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms. | pyrazine |
| selexipag | A member of the class of pyrazines that is N-(methanesulfonyl)-2-{4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetamide carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. An orphan drug used for the treatment of pulmonary arterial hypertension. It is a prodrug for ACT-333679 (the free carboxylic acid). | selexipag |
| sulfalene | sulfamethopyrazine | |
| telaprevir | An oligopeptide consisting of N-(pyrazin-2-ylcarbonyl)cyclohexylalanyl, 3-methylvalyl, octahydrocyclopenta[c]pyrrole-1-carboxy, and 3-amino-N-cyclopropyl-2-oxohexanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection. | telaprevir |
| tetramethylpyrazine | A member of the class of pyrazines that is pyrazine in which all four hydrogens have been replaced by methyl groups. An alkaloid extracted from Chuanxiong (Ligusticum wallichii). | tetramethylpyrazine |
| yoda 1 | A member of the class of thiadiazoles that is 1,3,4-thiadiazole substituted by pyrazin-2-yl and (2,6-dichlorobenzyl)sulfanediyl groups at positions 2 and 5, respectively. It is a selective activator of mechanosensitive channel piezo1. | yoda 1 |
Research
Studies (26,788)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4,506 (16.82) | 18.7374 |
| 1990's | 4,333 (16.18) | 18.2507 |
| 2000's | 5,303 (19.80) | 29.6817 |
| 2010's | 9,680 (36.14) | 24.3611 |
| 2020's | 2,966 (11.07) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 3,373 (9.44%) | 5.53% |
| Reviews | 3,049 (8.54%) | 6.00% |
| Case Studies | 2,411 (6.75%) | 4.05% |
| Observational | 120 (0.34%) | 0.25% |
| Other | 26,762 (74.93%) | 84.16% |